Targeted delivery of anti-cancer growth inhibitory peptides derived from human α-fetoprotein: Review of an international multi-center collaborative Study

Journal of Drug Targeting

Volumn 18, Issue 8, 2010, Pages 575-588

  Mizejewski, G J ^a   Mirowski, M ^c   Garnuszek, P ^b   Maurin, M ^b   Cohen, B D ^d   Poiesz, B J ^e   Posypanova, G A ^f,g   Makarov, V A ^g   Severin, E S ^h   Severin, S E ^f,g  

^a WADSWORTH CENTER   (United States)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNION COLLEGE   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f Moscow Research Institute of Medical Ecology   (Russian Federation)

^g I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^h Russian Research Center of Molecular Diagnostics and Therapy   (Russian Federation)

Author keywords

Fetoprotein; AFPep; Cancer cells; Cell surface; Growth inhibitory peptide; P149 peptide; Receptors; Targeted delivery

Indexed keywords

ALPHA FETOPROTEIN; AMINO ACID; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DOXORUBICIN; FLUORESCEIN; GROWTH INHIBITORY PEPTIDE 34; GROWTH INHIBITORY PEPTIDE 8; IODINE 125; NANOBEAD; TAMOXIFEN; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL MEMBRANE; COLON CANCER; CONJUGATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FLUORESCENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY TUMOR; LUNG CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN LOCALIZATION; REVIEW; TUMOR CELL;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GROWTH INHIBITORS; HUMANS; MULTICENTER STUDIES AS TOPIC; PEPTIDE FRAGMENTS;

EID: 77955215207     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003587243     Document Type: Review

References (47)

1. Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI. (2002). A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci USA, 99, 2211-2215.
2. Biddle W, Sarcione EJ. (1987). Specific cytoplasmic alpha-fetoprotein binding protein in MCF-7 human breast cancer cells and primary breast cancer tissue. Breast Cancer Res Treat, 10, 279-286.
3. Butterstein G, Morrison J, Mizejewski GJ. (2003). Effect of alpha-fetoprotein and derived peptides on insulin- and estrogen-induced fetotoxicity. Fetal Diagn Ther, 18, 360-369.
4. Butterstein GM, Mizejewski GJ. (1999). Alpha-fetoprotein inhibits frog metamorphosis: implications for protein motif conservation. Comp Biochem Physiol, Part A Mol Integr Physiol, 124, 39-45.
5. Eisele LE, Mesfin FB, Bennett JA, Andersen TT, Jacobson HI, Vakharia DD, MacColl R, Mizejewski GJ. (2001a). Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties. J Pept Res, 57, 539-546. (Pubitemid 32552195)
6. Eisele LE, Mesfin FB, Bennett JA, Andersen TT, Jacobson HI, Soldwedel H, MacColl R, Mizejewski GJ. (2001b). Studies on a growth-inhibitory peptide derived from alpha-fetoprotein and some analogs. J Pept Res, 57, 29-38. (Pubitemid 32057828)
7. Garnuszek P, Wiercioch R, Sztajer H, Karczmarczyk U, Mirowski M. (2005). Uptake of radiolabelled modified fragment of human alfafetoptrotein by experimental mammary adenocarcinoma: in vitro and in vivo studies. Nucl Med Rev Cent East Eur, 8, 6-10.
8. Hamza A, Sarma MH, Sarma RH. (2003). Plausible interaction of an alpha-fetoprotein cyclopeptide with the G-protein-coupled receptor model GPR30: docking study by molecular dynamics simulated annealing. J Biomol Struct Dyn, 20, 751-758.
9. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR. (1995). In vivo cultivation of tumor cells in hollow fibers. Life Sci, 57, 131-141.
10. Isensee J, Meoli L, Zazzu V, Nabzdyk C, Witt H, Soewarto D, Effertz K, Fuchs H, Gailus-Durner V, Busch D, Adler T, de Angelis MH, Irgang M, Otto C, Noppinger PR. (2009). Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology, 150, 1722-1730.
11. Kakinuma N, Sato M, Yamada T, Kohu K, Nakajima M, Akiyama T, Ohwada S, Shibanaka Y. (2005). Cloning of novel LERGU mRNAs in GPR30 3? untranslated region and detection of 2 bp-deletion polymorphism in gastric cancer. Cancer Sci, 96, 191-196.
12. Kanevsky VYu, Pozdnyakova LP, Aksenova OA, Severin SE, Katukov Vyu, Severin ES. (1997). Isolation and characterization of AFPbinding proteins from tumor and fetal human tissues. Biochem Mol Biol Int, 41, 1143-1151.
13. Line BR, Feustel PJ, Festin SM, Andersen TT, Dansereau RN, Lukasiewicz RL, Zhu S, Bennett JA. (1999). Scintigraphic detection of breast cancer xenografts with Tc-99m natural and recombinant human alpha-fetoprotein. Cancer Biother Radiopharm, 14, 485-494.
14. Lorenzo HC, Geuskens M, Macho A, Lachkar S, Verdiere-Sahuque M, Pineiro A, Uriel J. (1996). Alpha-fetoprotein binding and uptake by primary cultures of human skeletal muscle. Tumour Biol, 17, 251-260.
15. MacColl R, Eisele LE, Stack RF, Hauer C, Vakharia DD, Benno A, Kelly WC, Mizejewski GJ. (2001). Interrelationships among biological activity, disulfide bonds, secondary structure, and metal ion binding for a chemically synthesized 34-amino-acid peptide derived from alpha-fetoprotein. Biochim Biophys Acta, 1528, 127-134.
16. Maurin M, Garnuszek P, Karczmarczyk U, Mirowski M. (2008). Studies on 99mTc-labeling of the modified fragment of human a-fetoprotein (P149-QY). J Radioanalyt Nucl Chem, 275, 101-107.
17. Mesfin FB, Andersen TT, Jacobson HI, Zhu S, Bennett JA. (2001). Development of a synthetic cyclized peptide derived from alphafetoprotein that prevents the growth of human breast cancer. J Pept Res, 58, 246-256.
18. Mesfin FB, Bennett JA, Jacobson HI, Zhu S, Andersen TT. (2000). Alpha-fetoprotein-derived antiestrotrophic octapeptide. Biochim Biophys Acta, 1501, 33-43.
19. Mirowski M, SWitalska J, Wiercioch R, Byszewska E, Niewiadomska H, Michalska M. (2003). Uptake of radiolabelled alpha-fetoprotein by experimental mammary adenocarcinoma and adenoma: in vivo and in vitro studies. Nucl Med Commun, 24, 297-303.
20. Mizejewski G, Smith G, Butterstein G. (2004). Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors. Cell Biol Int, 28, 913-933.
21. Mizejewski GJ. (1995). Alpha-fetoprotein binding proteins: implications for transmembrane passage and subcellular localization. Life Sci, 56, 1-9.
22. Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy J. (1996). Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segment. Mol Cell Endocrinol, 118, 15-23.
23. Mizejewski GJ. (2001). Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood), 226, 377-408.
24. Mizejewski GJ. (2002). Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther, 2, 709-735.
25. Mizejewski GJ, MacColl R. (2003). Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol Cancer Ther, 2, 1243-1255.
26. Mizejewski GJ, Muehlemann M, Dauphinee M. (2006). Update of alpha fetoprotein growth-inhibitory peptides as biotherapeu- tic agents for tumor growth and metastasis. Chemotherapy, 52, 83-90.
27. Mizejewski GJ. (2007). The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent. Cancer Biother Radiopharm, 22, 73-98.
28. Mizejewskia GJ, Butterstein G. (2006a). A Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects. Curr Protein Pept Sci, 7, 73-100.
29. Moro R, Tamaoki T, Wegmann TG, Longenecker BM, Laderoute MP. (1993). Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-fetoprotein receptor. Tumour Biol, 14, 116-130.
30. Muehlemann M, Miller KD, Dauphinee M, Mizejewski GJ. (2005). Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis. Cancer Metastasis Rev, 24, 441-467.
31. Naval J, Villacampa MJ, Goguel AF, Uriel J. (1985). Cell-type-specific receptors for alpha-fetoprotein in a mouse T-lymphoma cell line. Proc Natl Acad Sci USA, 82, 3301-3305.
32. Pal S, Wu LP. (2009). Pattern recognition receptors in the fly: lessons we can learn from the Drosophila melanogaster immune system. Fly (Austin), 3, 121-129.
33. Prevost G, Provost P, Salle V, Lanson M, Thomas F. (1993). A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours. Eur J Cancer, 29A, 1589-1592.
34. Severin SE, Moskaleva EYu, Shmyrev II, Posypanova GA, Belousova YuV, Sologub VK, Luzhkov YuM, Nakachian R, Andreani J, Severin ES. (1995). Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro. Biochem Mol Biol Int, 37, 385-392.
35. Severin SE. (1996). In vivo anti-tumor activity of cytotoxic drugs conjugated with human alpha fetoprotein. Tumor Target, 2, 299-306.
36. Shields GC. (2009). Computational approaches for the design of peptides with anti-breast cancer properties. Future Med Chem, 1, 201-212.
37. Srikrishna G, Freeze HH. (2009). Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia, 11, 615-628.
38. Suzuki Y, Zeng CQ, Alpert E. (1992). Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. J Clin Invest, 90, 1530-1536.
39. Teng SF, Sproule K, Husain A, Lowe CR. (2000). Affinity chromatography on immobilized "biomimetic" ligands. Synthesis, immobilization and chromatographic assessment of an immunoglobulin G-binding ligand. J Chromatogr B Biomed Sci Appl, 740, 1-15.
40. Torres CG, Pino AM, Sierralta WD. (2009). A cyclized peptide derived from alpha fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep, 21, 1397-1404.
41. Torres JM, Darracq N, Uriel J. (1992a). Membrane proteins from lym- phoblastoid cells showing cross-affinity for alpha-fetoprotein and albumin. Isolation and characterization. Biochim Biophys Acta, 1159, 60-66.
42. Torres JM, Geuskens M, Uriel J. (1992b). Activated human T lymphocytes express albumin binding proteins which cross-react with alpha-fetoprotein. Eur J Cell Biol, 57, 222-228.
43. Torres JM, Laborda J, Naval J, Darracq N, Calvo M, Mishal Z, Uriel J. (1989). Expression of alpha-fetoprotein receptors by human T-lymphocytes during blastic transformation. Mol Immunol, 26, 851-857. (Pubitemid 19249462)
44. Uriel J, Failly-Crepin C, Villacampa MJ, Pineiro A, Geuskens M. (1984a). Incorporation of alphafetoprotein by the MCF-7 human breast cancer cell line. Tumour Biol, 5, 41-51.
45. Uriel J, Villacampa MJ, Moro R, Naval J, Failly-Crepin C. (1984b). Uptake of radiolabeled alpha-fetoprotein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. Cancer Res, 44, 5314-5319.
46. Vakharia D, Mizejewski GJ. (2000). Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res Treat, 63, 41-52.
47. Villacampa MJ, Moro R, Naval J, Failly-Crepin C, Lampreave F, Uriel J. (1984). Alpha-fetoprotein receptors in a human breast cancer cell line. Biochem Biophys Res Commun, 122, 1322-1327. (Pubitemid 14073567)